Posted by iforgotmypassword on April 28, 2008, at 17:10:06
i posted this before. they mention these autoantibodies showing up in CFS cases, but who knows who else they may show up in... "difficulty thinking" mentioned as a primary symptom looked at. executive functions in CFS are often described as being blown, dead and useless. and that CFS is a neurological disorder of not being able to sort out irrelevant stimuli, overwhelming and disabling the persons cognitive ability, leading to the "subjective" exhaustion.
may show a relation to: atypical depression, executive dysfunction, anhedonia, apathy, pathological indecision/avolition...
...hoarding (clarified as a dysexecutive syndrome not a collecting syndrome), loss of meaningful fluency, feelings of emotional and cognitive paralysis and inertia...
any of these, seem so related. as just feeling as if they are effective death of the person, just leaving the organism.
- - - - -
here is the article:
- - - - -Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome
SUSUMU TANAKA1, HIROHIKO KURATSUNE2,3, YOH HIDAKA1, YUKIKO HAKARIYA2, KE-ITA TATSUMI1,
TORU TAKANO1, YUZURU KANAKURA2 and NOBUYUKI AMINO1
Departments of 1Laboratory Medicine and 2Molecular Medicine, Hematology and Oncology,
Osaka University Medical School, Suita, Osaka 585-0871; 3Faculty of Health Science for Welfare,
Kansai University of Welfare Sciences, Kasiwara, Osaka 582-0026, Japan
Received February 5, 2003; Accepted April 4, 2003Abstract.
The disturbance of the central nervous system and immunological abnormalities have been suggested in patients with chronic fatigue syndrome (CFS). We focused on immunological abnormalities against neurotransmitter receptors in CFS. Using a sensitive radioligand assay, we examined serum autoantibodies to recombinant human muscarinic cholinergic receptor 1 (CHRM1), mu-opioid receptor (OPRM1), 5-hydroxytryptamine receptor 1A (HTR1A), and dopamine receptor D2 (DRD2) in patients with CFS (n=60) and results were compared with those in patients with autoimmune disease (n=33) and in healthy controls (n=30). The mean anti-CHRM1 antibody index was significantly higher in patients with CFS (p<0.0001) and autoimmune disease (p<0.05) than that in healthy controls, and positive reaction was found in 53.3% of patients with CFS. Anti-OPRM1 antibodies, anti-HTR1A antibodies, and anti-DRD2 antibodies were found in 15.2, 1.7, and 5.0% of patients with CFS, respectively. Anti-nuclear antibodies were found in 56.7% (34/60) of patients with CFS, but anti-nuclear antibody titers did not correlate with the activities of the above four autoantibodies. The patients with positive autoantibodies to CHRM1 had a significantly higher mean score (1.81) of feeling of muscle weakness than negative patients (1.18) among CFS patients (p<0.01). Higher scores on painful node, forgetfulness, and difficulty thinking were also found in CFS patients with anti-CHRM1 antibodies but did not reach statistical significance. In conclusion, autoantibodies to CHRM1 were detected in a large number of CFS patients and were related to CFS symptoms. Our findings suggested that subgroups of CFS are associated with autoimmune abnormalities of CHRM1.
Full-text: http://histology1.med.uoc.gr/IJMM/2003/volume12/number2/225.pdf
poster:iforgotmypassword
thread:826103
URL: http://www.dr-bob.org/babble/neuro/20080418/msgs/826103.html